Intermittent Versus Continuous Surface O2 During HMP of DCD Kidneys (HMPO2)
Primary Purpose
Delayed Graft Function, Kidney Transplant; Complications, Ischemia Reperfusion Injury
Status
Recruiting
Phase
Phase 3
Locations
Belgium
Study Type
Interventional
Intervention
Oxygen
Sponsored by
About this trial
This is an interventional treatment trial for Delayed Graft Function focused on measuring Hypothermic oxygenated machine perfusion, Kidney preservation, bubble and surface oxygenation
Eligibility Criteria
Inclusion Criteria:
- Listed for a renal transplantation due to end stage renal disease
- Willingness to comply with the protocol procedures for the duration of the study included scheduled follow-up visits and examinations.
Exclusion Criteria:
- Multi-organ recipients
- Dual kidney transplantation
Sites / Locations
- Cliniques Universitaires Saint-LucRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
I-HMPO2
C-HMPO2
Arm Description
intermittent surface oxygenation during hypothermic machine perfusion (surface oxygenation interrupted during organ transport)
continuous surface oxygenation during HMP (surface oxygenation during the whole machine preservation period included organ transport)
Outcomes
Primary Outcome Measures
Functional delayed graft function
defined as the absence of a decrease in the serum creatinine level of at least 10% per day for at least 3 consecutive days in the first 7 days after transplantation (not including patients in whom acute rejection of calcineurin inhibitor toxicity is proven on biopsy)
Secondary Outcome Measures
Need for dialysis after transplantation
Number of dialysis sessions after transplantation
Delayed graft function
defined as the need for dialysis in the first 7 days after transplantation and preceding the return of kidney function
Serum creatinine reduction ratio
alternative definition of DGF= CRR2 < or = 30%
Graft survival
Functional kidney graft at 7 days, 3, 6, and 12 months
Patient survival (censored and uncensored for death)
Patient survival at 7 days, 3, 6, and 12 months
Glomerular filtration rate at 1 year after transplantation
24-hour creatinine clearance
Estimated glomerular filtration rate
eGFR defined by the CKD-EPI equation (Chronic Kidney Disease Epidemiology Collaboration) at 3, 6 and 12 months after transplantation
Primary non-function
defined as the continued need for dialysis at 3 months after transplantation
Biopsy-proven acute rejection
Biopsy-proven acute rejection during the 1 year after transplantation
Metabolic analysis on kidney preservation tissue
Metabolic analysis by 1D proton NMR (e.g., succinate, lactate, acetate, formate, hypoxanthine) on a tissue sample taken before (= baseline) and at the end of the preservation period before transplantation of the kidney
Metabolic analysis on kidney preservation tissue
Metabolic analysis by liquid chromatography coupled to electrospray ionization mass spectrometry (LC-ESI-MS) (succinate, glutamate, lactate, ATP, ADP, AMP, NADH, NAD+) on a tissue sample taken before (= baseline) and at the end of the preservation period before transplantation of the kidney
Metabolic analysis on preservation fluid
Metabolic analysis by 1D proton NMR and fluorescence on a perfusion fluid sample taken before (= baseline) and at the end of the preservation period before transplantation of the kidney
Full Information
NCT ID
NCT05430620
First Posted
June 17, 2022
Last Updated
June 23, 2022
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
1. Study Identification
Unique Protocol Identification Number
NCT05430620
Brief Title
Intermittent Versus Continuous Surface O2 During HMP of DCD Kidneys
Acronym
HMPO2
Official Title
A Prospective Feasibility Trail to Compare the Efficacy of Intermittent Surface Oxygenation With Continuous Surface Oxygenation During Hypothermic Machine Perfusion of Kidneys Donated After Circulatory Death
Study Type
Interventional
2. Study Status
Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 20, 2022 (Actual)
Primary Completion Date
January 1, 2025 (Anticipated)
Study Completion Date
January 1, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of the study is to evaluate the feasibility of this bubble and surface oxygenation and to determine the optimal timing of surface oxygenation (continuous versus intermittent) as alternative for membrane-oxygenated kidneys, originating from DCD donors, during HMP on early graft function in clinical practice.
Detailed Description
Kidneys originating from deceased donors after circulatory death (DCD), category 3 and 5 (controlled) will be preserved from procurement until transplantation on hypothermic machine perfusion conditions and prospectively randomized into 2 study groups: 1) intermittent surface oxygenation during HMP (surface oxygenation interrupted during organ transport (2-4h)(I-HMPO2 group), and 2) continuous surface oxygenation during HMP (surface oxygenation during the whole machine preservation period included organ transport)(C-HMPO2 group).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Delayed Graft Function, Kidney Transplant; Complications, Ischemia Reperfusion Injury, Mitochondrial
Keywords
Hypothermic oxygenated machine perfusion, Kidney preservation, bubble and surface oxygenation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Kidneys originating from deceased donors after circulatory death (DCD), category 3 and 5 (controlled) will be preserved from procurement until transplantation on hypothermic machine perfusion conditions and prospectively randomized into 2 study groups: 1) intermittent surface oxygenation during HMP (surface oxygenation interrupted during organ transport (2-4h)(I-HMPO2 group), and 2) continuous surface oxygenation during HMP (surface oxygenation during the whole machine preservation period included organ transport)(C-HMPO2 group)
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
I-HMPO2
Arm Type
Experimental
Arm Description
intermittent surface oxygenation during hypothermic machine perfusion (surface oxygenation interrupted during organ transport)
Arm Title
C-HMPO2
Arm Type
Active Comparator
Arm Description
continuous surface oxygenation during HMP (surface oxygenation during the whole machine preservation period included organ transport)
Intervention Type
Drug
Intervention Name(s)
Oxygen
Other Intervention Name(s)
feasibility of bubble and surface oxygenation applied to the LifePort Kidney Transporter (Organ Recovery Systems, Diegem, Belgium)
Intervention Description
Active oxygenation during hypothermic machine perfusion by bubble and surface oxygenation. Intermittent surface oxygenation is compared with continuous surface oxygenation during hypothermic machine perfusion
Primary Outcome Measure Information:
Title
Functional delayed graft function
Description
defined as the absence of a decrease in the serum creatinine level of at least 10% per day for at least 3 consecutive days in the first 7 days after transplantation (not including patients in whom acute rejection of calcineurin inhibitor toxicity is proven on biopsy)
Time Frame
first 7 days after transplantation
Secondary Outcome Measure Information:
Title
Need for dialysis after transplantation
Description
Number of dialysis sessions after transplantation
Time Frame
0-30 days after transplantation
Title
Delayed graft function
Description
defined as the need for dialysis in the first 7 days after transplantation and preceding the return of kidney function
Time Frame
first 7 days after transplantation
Title
Serum creatinine reduction ratio
Description
alternative definition of DGF= CRR2 < or = 30%
Time Frame
Day 1-2 after transplantation
Title
Graft survival
Description
Functional kidney graft at 7 days, 3, 6, and 12 months
Time Frame
From 1-365 days after transplantation
Title
Patient survival (censored and uncensored for death)
Description
Patient survival at 7 days, 3, 6, and 12 months
Time Frame
From 1-365 days after transplantation
Title
Glomerular filtration rate at 1 year after transplantation
Description
24-hour creatinine clearance
Time Frame
At 1 year after transplantation (window 30 days)
Title
Estimated glomerular filtration rate
Description
eGFR defined by the CKD-EPI equation (Chronic Kidney Disease Epidemiology Collaboration) at 3, 6 and 12 months after transplantation
Time Frame
At 3, 6, and 12 months after transplantation with window of 10 days
Title
Primary non-function
Description
defined as the continued need for dialysis at 3 months after transplantation
Time Frame
Until 3 months after transplantation
Title
Biopsy-proven acute rejection
Description
Biopsy-proven acute rejection during the 1 year after transplantation
Time Frame
Until 1 year after transplantation with window of 10 days
Title
Metabolic analysis on kidney preservation tissue
Description
Metabolic analysis by 1D proton NMR (e.g., succinate, lactate, acetate, formate, hypoxanthine) on a tissue sample taken before (= baseline) and at the end of the preservation period before transplantation of the kidney
Time Frame
Baseline and pre-surgery
Title
Metabolic analysis on kidney preservation tissue
Description
Metabolic analysis by liquid chromatography coupled to electrospray ionization mass spectrometry (LC-ESI-MS) (succinate, glutamate, lactate, ATP, ADP, AMP, NADH, NAD+) on a tissue sample taken before (= baseline) and at the end of the preservation period before transplantation of the kidney
Time Frame
Baseline and pre-surgery
Title
Metabolic analysis on preservation fluid
Description
Metabolic analysis by 1D proton NMR and fluorescence on a perfusion fluid sample taken before (= baseline) and at the end of the preservation period before transplantation of the kidney
Time Frame
Baseline and pre-surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Listed for a renal transplantation due to end stage renal disease
Willingness to comply with the protocol procedures for the duration of the study included scheduled follow-up visits and examinations.
Exclusion Criteria:
Multi-organ recipients
Dual kidney transplantation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tom Darius, Phd
Phone
003227642218
Email
tom.darius@saintluc.uclouvain.be
First Name & Middle Initial & Last Name or Official Title & Degree
Nathalie Staumont
Phone
003227642218
Email
nathalie.Staumont@saintluc.uclouvain.be
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tom Darius, MD, PhD
Organizational Affiliation
Cliniques universitaires Saint-Luc
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cliniques Universitaires Saint-Luc
City
Brussel
State/Province
Woluwé-Saint-Lambert
ZIP/Postal Code
1200
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tom Darius, MD, PhD
Phone
+3227646065
Email
tom.darius@saintluc.uclouvain.be
First Name & Middle Initial & Last Name & Degree
Nathalie Staumont
Phone
+3227642218
Email
nathalie.staumont@saintluc.uclouvain.be
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Intermittent Versus Continuous Surface O2 During HMP of DCD Kidneys
We'll reach out to this number within 24 hrs